Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
clinical trials
deals
alexion pharmaceuticals
autoimmune disorders
fda
national top stories
startups
20/20 healthcare partners
allosteric
alnylam pharmaceuticals
amgen ventures
amyotrophic lateral sclerosis
amyotrophic lateral sclerosis (als)
anthony despasqua
atlas venture
atopic dermatitis
boehringer ingelheim
brace pharma
christian angermayer
cleva pharma
complement system
dicerna pharamceuticals
dolby family ventures
drug discovery
dupilumab
enclear therapies
financing
funding
generalized myasthenia gravis
gf securities
glaxosmithkline
global health sciences fund
hepatitis b
hepatitis b virus
What
disease
4
×
medicines
drug
new
pharma
pharmaceuticals
potential
address
adds
ago
allosteric
alternative
associated
autoimmune
candidate
caught
causing
clinic
companies
deal
develop
device
dialysis
dicerna
diseases
drugs
elusive
enclear
expensive
eye
gene
harmful
hepatitis
hotspot
intended
lead
molecules
nets
neuro
neurodegenerative
Language
unset
Current search:
biotech
×
disease
×
boston
×
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
